AstraZeneca, One MedImmune Way, Gaithersburg, Maryland, 20878, USA.
J Nanosci Nanotechnol. 2019 Jul 1;19(7):3798-3803. doi: 10.1166/jnn.2019.16735.
The fluorescence labeling of aptamers is a useful technology for aptamer tracking and imaging on the cells. The aptamer SL₂-B, against the heparin binding domain (HBD) of VEGF protein, was linked to QDs, producing the QD-SL₂-B aptamer conjugate. The QDs and the QD-aptamer conjugate were characterized and photobleaching effect was studied prior to the cellular incubation. Fluorescence imaging showed that the QD-SL₂-B aptamer conjugate could specifically recognize Hep G2 liver cancer cells and is taken up by the cells without addition of any external transfecting or cell permeabilizing agent. In addition, the results also indicate that incubation time is important for the aptamer cellular uptake and to exhibit its antiproliferative activity on Hep G2 liver cancer cells. This QDs labeling technique provides a new strategy for labeling aptamer molecules for aptamer detection, imaging and understanding their cellular uptake.
适配体的荧光标记是一种用于适配体在细胞上跟踪和成像的有用技术。针对 VEGF 蛋白肝素结合域(HBD)的适配体 SL₂-B 与量子点(QD)相连,生成 QD-SL₂-B 适配体缀合物。对 QD 和 QD-适配体缀合物进行了表征,并在细胞孵育前研究了光漂白效应。荧光成像显示,QD-SL₂-B 适配体缀合物能够特异性识别 Hep G2 肝癌细胞,并在不添加任何外部转染或细胞通透剂的情况下被细胞摄取。此外,结果还表明,孵育时间对适配体的细胞摄取以及在 Hep G2 肝癌细胞上表现出的抗增殖活性很重要。该 QD 标记技术为标记适配体分子以进行适配体检测、成像以及理解其细胞摄取提供了一种新策略。